A Review on Nanostructured Electrochemical Immunosensors for the Determination of HER2, a Breast Cancer Biomarker

Caglar Berkel; Oguz Özbek; Onur Cem Altunoluk; İsa Mert Eski

doi:10.5281/zenodo.18056046

Authors

Caglar Berkel Tokat Gaziosmanpaşa University https://orcid.org/0000-0003-4787-5157
Oguz Özbek Tokat Gaziosmanpaşa University https://orcid.org/0000-0001-5185-9681
Onur Cem Altunoluk Tokat Gaziosmanpaşa University https://orcid.org/0000-0003-3558-3499
İsa Mert Eski Tokat Gaziosmanpaşa University https://orcid.org/0009-0000-8192-0340

DOI:

https://doi.org/10.5281/zenodo.18056046

Keywords:

Nanostructure, cancer, HER2, immunosensor, electrochemistry

Abstract

The amplification or overexpression of HER2, which is observed in approximately 15–20 % of breast cancer patients, is known to be associated with unfavorable prognosis in patients with breast cancer. Current techniques which have been approved for the detection of HER2 status such as in-situ hybridization (ISH) and immunohistochemistry (IHC) are costly, time-consuming, have limited sensitivity and selectivity, and also very invasive, limiting their applicability at the clinic in certain settings. However, electrochemical biosensors are most appropriate based on their relative simplicity with respect to instrumentation and analysis, low cost per assay, high selectivity and superior sensitivity, reliability, fast response time and their potential for miniaturization and scalability. Electrochemical immunosensors have shown promise as fast, easy to fabricate, low-cost, and sensitive sensors for the determination of HER2 mRNA/protein levels. These biosensors take advantage of chemical stability, high surface area, and biocompatibility of antibodies, their high affinity and specificity, and unique conductive properties of nanomaterials to selectively and sensitively determine HER2 levels in biological fluids. In this review, we covered electrochemical immunosensors developed for the determination of HER2 levels in biological fluids such as human serum. We highlighted specific sensing capabilities and analytical performance parameters of these immunosensors, also detailing the design of these electrochemical HER2 immunosensors.

Author Biographies

Caglar Berkel, Tokat Gaziosmanpaşa University

Department of Molecular Biology and Genetics, Faculty of Science and Arts, Tokat Gaziosmanpaşa University, 60250, Tokat, Türkiye

Oguz Özbek, Tokat Gaziosmanpaşa University

Department of Molecular Biology and Genetics, Faculty of Science and Arts, Tokat Gaziosmanpaşa University, 60250, Tokat, Türkiye

Onur Cem Altunoluk, Tokat Gaziosmanpaşa University

Department of Chemistry, Faculty of Science and Arts, Tokat Gaziosmanpaşa University, 60250, Tokat, Türkiye

İsa Mert Eski, Tokat Gaziosmanpaşa University

Department of Molecular Biology and Genetics, Faculty of Science and Arts, Tokat Gaziosmanpaşa University, 60250, Tokat, Türkiye

References

E. Carvalho, S. Canberk, F. Schmitt, N. Vale, N., Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies, Cancers 17 (7), 1102 (2025).

Berkel, C., Increased NINJ1 expression in hormone receptor-positive breast tumors: implications for prognosis, Genome Instability & Disease 6, 29–41 (2025).

Swain, SM., Shastry, M., Hamilton, E., Targeting HER2-positive breast cancer: advances and future directions, Nature reviews. Drug discovery 22 (2), 101-126 (2023).

Zhao, J., Zhou, Z., Saw, PE., Song, E., Silver Jubilee of HER2 targeting: a clinical success in breast cancer, Journal of the National Cancer Center 5 (4), 379-391 (2025).

Okines, AFC., Curigliano, G., Mizuno, N., Oh, DY., Rorive, A., Soliman, H., Takahashi, S., Bekaii-Saab, T., Burkard, ME., Chung, KY., Debruyne, PR., Fox, JR., Gambardella, V., Gil-Martin, M., Hamilton, EP., Monk, BJ., Nakamura, Y., Nguyen, D., O'Malley, DM., Olawaiye, AB., Pothuri, B., Reck, M., Sudo, K., Sunakawa, Y., Van Marcke, C., Yu, EY., Ramos, J., Tan, S., Bieda, M., Stinchcombe, TE., Pohlmann, PR., Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial, Nature Medicine 31 (3), 909-916 (2025).

Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., Sawada, K., Taniguchi, H., Fuse, N., Nomura, S., Fukui, M., Matsuda, S., Sakamoto, Y., Uchigata, H., Kitajima, K., Kuramoto, N., Asakawa, T., Olsen, S., Odegaard, JI., Sato, A., Fujii, S., Ohtsu, A., Yoshino, T., Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial, Nature Medicine 27, 1899–1903 (2021).

Murthy, RK., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, SA., Lin, NU., Borges, V., Abramson, V., Anders, C., Bedard, PL., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, SS., Müller, V., Braga, S., Duhoux, FP., Greil, R., Cameron, D., Carey, LA., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, MC., Walker, L., Feng, W., Winer, EP., Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer, The New England journal of medicine 382 (7), 597–609 (2020).

Strickler, JH., Cercek, A., Siena, S., André, T., Ng, K., Cutsem, EV., Wu, C., Paulson, AS., Hubbard, JM., Coveler, AL., Fountzilas, C., Kardosh, A., Kasi, PM., Lenz, HJ., Ciombor, KK., Elez, E., Bajor, DL., Cremolini, C., Sanchez, F., Stecher, M., Feng, W., Bekaii-Saab, TS., MOUNTAINEER investigators Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study, The Lancet. Oncology 24 (5), 496–508 (2023).

Cortés, J., Kim, S., Chung, W., Im, S., Park, YH., Hegg, R., Kim, MH., Tseng, LM., Petry, V., Chung, CF., Iwata, H., Hamilton, E., Curigliano, G., Xu, B., Huang, CS., Kim, JH., Chiu, JWY., Pedrini, JL., Lee, C., Liu, Y., Cathcart, J., Bako, E., Verma, S., Hurvitz, SA., DESTINY-Breast03 Trial Investigators Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer, The New England journal of medicine 386 (12), 1143–1154 (2022).

Shitara, K., Bang, Y., Iwasa, S., Sugimoto, N., Ryu, MH., Sakai, D., Chung, HC., Kawakami, H., Yabusaki, H., Lee, J., Saito, K., Kawaguchi, Y., Kamio, T., Kojima, A., Sugihara, M., Yamaguchi, K., Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. The New England journal of medicine 382 (25), 2419–2430 (2020).

Krop, I., Krop, IE., Kim, SB., Martin, AG., LoRusso, PM., Ferrero, JM., Badovinac-Crnjevic, T., Hoersch, S., Smitt, M., Wildiers, H., Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial, The Lancet. Oncology 18 (6), 743–754 (2017).

Loibl, S., Gianni, L., HER2-positive breast cancer, Lancet 389, 2415–2429 (2017).

Callari, M., Dugo, M., Barreca, M., Győrffy, B., Galbardi, B., Vigano, L., Locatelli, A., Dall'Ara, C., Ferrarini, M., Bisagni, G., Colleoni, M., Mansutti, M., Zamagni, C., Del Mastro, L., Zambelli, S., Frassoldati, A., Biasi, O., Pusztai, L., Valagussa, P., Viale, G., Gianni, L., Bianchini, G., Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies, nature communications 16 (1), 2195 (2025).

Swain, SM., Swain, SM., Miles, D., Kim, S., Im, YH., Im, S., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., Clark, E., Knott, A., Restuccia, E., Benyunes, MC., Cortés, J., Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, The Lancet. Oncology 21, 519–530 (2020).

Miles, D., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Campone, M., Bondarenko, I., Nowecki, Z., Errihani, H., Paluch-Shimon, S., Wardley, A., Merot, JL., Trask, P., Toit, Y., Pena-Murillo, C., Revelant, V., Klingbiel, D., Bachelot, T., Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication, Annals of oncology : official journal of the European Society for Medical Oncology 32 (10), 1245–1255 (2021).

Xu, B., Shen, J., Guo, W., Zhao, W., Zhuang, Y., Wang, L., Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer. Pathology - Research and Practice 215, 251–255 (2019).

Zhang, M., Gao, G., Ding, Y., Deng, C., Xiang, J., Wu, H., A fluorescent aptasensor for the femtomolar detection of epidermal growth factor receptor-2 based on the proximity of G-rich sequences to Ag nanoclusters, Talanta 199, 238–243 (2019).

Shen, C., Liu, S., Li, X., Zhao, D., Yang, M., Immunoelectrochemical detection of the human epidermal growth factor receptor 2 (HER2) via gold nanoparticle-based rolling circle amplification, Microchim Acta 185 (12), 547–553 (2018).

Perrier, A., Gligorov, J., Lefevre, G., Boissan, M., The extracellular domain of Her2 in serum as a biomarker of breast cancer, Laboratory Investigation, 98 (6), 696-707 (2018).

Chai, Y., Li, X., Yang, M., Aptamer based determination of the cancer biomarker HER2 by using phosphate-functionalized MnO2 nanosheets as the electrochemical probe, Microchim Acta 186, 316–322 (2019).

Pacheco, JG., Rebelo, P., Freitas, M., Nouws, HPA., Delerue-Matos, C., Breast cancer biomarker (HER2-ECD) detection using a molecularly imprinted electrochemical sensor, Sensors and Actuators B: Chemical 273, 1008–1014 (2018).

Sharma, S., Zapatero-Rodríguez, J., Saxena, R., O’Kennedy, R., Srivastava, S., Ultrasensitive direct impedimetric immunosensor for detection of serum HER2, Biosensors and Bioelectronics 106, 78–85 (2018).

Altunoluk, OC., Özbek, O., Kalay, E., Berkel, C., Isildak, Ö., Synthesis and use of novel rhodanine derivatives to fabricate potentiometric sensors for the determination of toxic heavy metal ions. Microchemical Journal 218, 115090 (2025).

Berkel, C., Özbek, O., Green electrochemical sensors, their applications and greenness metrics used: A review, Electroanalysis 36 (11), e202400286 (2024).

Özbek, O., Eski, IM., Berkel, C., Success of electrochemical biosensors developed for the determination of amyloid-beta 42 (Aβ42) protein in the diagnosis of Alzheimer’s disease, Genome Instability & Disease 6, 347-350 (2025).

Isildak, Ö., Güneş, G., Özbek, O., Use of some amino acid potentiometric biosensors as detectors in ion chromatography, Chemical Papers 77 (6), 3317-3325 (2023).

Özbek, O., Berkel, C., Isildak, Ö., Isildak, I., Potentiometric urea biosensors, Clinica Chimica Acta 524, 154-163 (2022).

Özbek, O., Isildak, Ö., Isildak, I., A potentiometric biosensor for the determination of valproic acid: human blood–based study of an anti–epileptic drug, Biochemical Engineering Journal 176, 108181 (2021).

Yola, ML., Sensitive sandwich-type voltammetric immunosensor for breast cancer biomarker HER2 detection based on gold nanoparticles decorated Cu-MOF and Cu2ZnSnS4 NPs/Pt/g-C3N4 composite, Microchim Acta 188, 78 (2021).

Adabi, M., Esnaashari, SS., Adabi, M., An electrochemical immunosensor based on electrospun carbon nanofiber mat decorated with gold nanoparticles and carbon nanotubes for the detection of breast cancer, Journal of Porous Materials 28, 415–421 (2021).

Freitasa, M., Nouwsa, HPA., Keatingb, E., Delerue-Matos, C., High-performance electrochemical immunomagnetic assay for breast cancer analysis, Sensors and Actuators B: Chemical 308, 127667 (2020).

Freitas, M., Neves, MMPS., Nouws, HPA., Delerue-Matos, C., Quantum dots as nanolabels for breast cancer biomarker HER2-ECD analysis in human serum, Talanta 208, 120430 (2020).

Tallapragada, SD., Layek, K., Mukherjee, R., Mistry, KK., Ghosh, M., Development of screen-printed electrode based immunosensor for the detection of HER2 antigen in human serum samples, Bioelectrochemistry 118, 25-30 (2017).

da Silva, W., Gerôncio, ETS., Goulart, MOF., A novel immunosensor based on nanostructured modified electrodes with a conductive copolymer film and gold nanoparticles electrodeposited in ethaline deep eutectic solvent (DES) for the detection of the HER2 ECD breast cancer biomarker, Journal of Solid State Electrochemistry 29, 2335–2350 (2025).

Xia, Q., Mu, Z., Qing, M., Zhou, J., Bai, L., A sandwich-type electrochemical immunosensor for sensitive detection of HER2 based on dual signal amplification of La-MOF-PbO2 and PEI-MoS2NFs composites, Bioelectrochemistry 152, 108431 (2023).

Sakthivel, R., Lin, Y., Yu, M., Dhawan, U., Liu, X., Chen, J., Tung, C., Ch, R., A sensitive sandwich-type electrochemical immunosensor using nitrogen-doped graphene/metal-organic framework-derived CuMnCoOx and Au/MXene for the detection of breast cancer biomarker, Colloids and Surfaces B: Biointerfaces 234, 113755 (2024).

Amir, H., Subramanian, V., Sornambikai, S., Ponpandian, N., Visw, C., Nitrogen-enhanced carbon quantum dots mediated immunosensor for electrochemical detection of HER2 breast cancer biomarker, Bioelectrochemistry 155, 108589 (2024).

Dervisevic, M., Alba, M., Adams, TE., Prieto-Simon, B., Voelcker, NH., Electrochemical immunosensor for breast cancer biomarker detection using high-density silicon microneedle array, Biosensors and Bioelectronics 192, 113496 (2021).

Olorundare, FOG., Makaluza, S., Midzi, N., Arotiba, OA., Nkosi, D., A nanoDiamond/gold nanoparticle-based electrochemical immunosensor for the detection of HER 2 cancer biomarker, Biosensors and Bioelectronics: X 18, 100483 (2024).

Lah, Zmanh., Ahmada, SAA., Zaini, MS., Kamarudin, MA., An Electrochemical Sandwich Immunosensor for the Detection of HER2 using Antibody-Conjugated PbS Quantum Dot as a label, Journal of Pharmaceutical and Biomedical Analysis 174, 608-617 (2019).

Ehzari, H., Samimi, M., Safari, M., Gholivand, MB., Label-free electrochemical immunosensor for sensitive HER2 biomarker detection using the core-shell magnetic metal-organic frameworks, Journal of Electroanalytical Chemistry 877, 114722 (2020).

Atabay, SA., Ahmadzadeh, H., Norouzi, P., Dianat, S., Dashtian, K., Development of a sensitive antibody-based label-free electrochemical immunosensors for breast cancer diagnosis, Sensing and Bio-Sensing Research 48, 100793 (2025).

Rawat, R., Roy, S., Goswami, T., Mirsafi, AS., Ismael, M., Leissner, T., Mishra, YK., McLaughlin, J., Kant, K., Mathur, A., Aptamer-enhanced ultrasensitive electrochemical detection of HER-2 in breast cancer diagnosis using ZnO tetrapod-K4PTC nanohybrids, scientific reports 15, 17173 (2025).

Ma, Q., Dual-Mode Electrochemical Immunosensor Based on Au@Ag NRs as Double Signal Indicator for Sensitive Detection of HER2, Journal of The Electrochemical Society 168, 027515 (2021).

Joshi, A., GK, AV., Dhruv, D., Kurpad, V., Pandya, HJ., Morphology-Tuned Electrochemical Immunosensing of a Breast Cancer Biomarker Using Hierarchical Palladium Nanostructured Interfaces, ACS Omega 7 (38), 34177–341892022 (2022).

Zhang, Y., Xu, Y., Li, N., Qi, N., Peng, L., Yang, M., Hou, C., Huo, D., An ultrasensitive dual-signal ratio electrochemical aptamer biosensor for the detection of HER2, Colloids and Surfaces B: Biointerfaces 222, 113118 (2023).

Harahsheh, T., Makableh, YF., Rawashdeh, I., Al-Fandi, M., Enhanced aptasensor performance for targeted HER2 breast cancer detection by using screen-printed electrodes modified with Au nanoparticles, Biomed Microdevices 23, 46 (2021).

Rostamabadi, PF., Heydari-Bafrooei, E., Impedimetric aptasensing of the breast cancer biomarker HER2 using a glassy carbon electrode modified with gold nanoparticles in a composite consisting of electrochemically reduced graphene oxide and single-walled carbon nanotubes, Microchim Acta 186, 495 (2019).